2Xideas
CRL icon

2Xideas’s Charles River Laboratories CRL Stock Holding History

2Xideas’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-36,758
Closed -$6.79M – 62
2024
Q4 		$6.79M Sell
36,758
-386
-1% -$74.4K 0.91% 41
2024
Q3 		$7.32M Sell
37,144
-5,266
-12% -$1.09M 0.99% 49
2024
Q2 		$8.76M Sell
42,410
-116
-0.3% -$26.3K 1.09% 47
2024
Q1 		$11.5M Sell
42,526
-12,638
-23% -$3.02M 1.41% 28
2023
Q4 		$13M Sell
55,164
-3,467
-6% -$682K 1.4% 27
2023
Q3 		$11.5M Buy
58,631
+781
+1% +$160K 1.27% 30
2023
Q2 		$12.2M Buy
57,850
+9,330
+19% +$1.86M 1.16% 37
2023
Q1 		$9.8M Buy
48,520
+1,939
+4% +$439K 0.94% 55
2022
Q4 		$10.2M Buy
46,581
+9
+0% +$1.96K 1.07% 37
2022
Q3 		$9.16M Sell
46,572
-637
-1% -$138K 0.97% 32
2022
Q2 		$10.1M Buy
47,209
+4,791
+11% +$1.17M 0.92% 45
2022
Q1 		$12M Buy
42,418
+6,561
+18% +$2.02M 0.85% 54
2021
Q4 		$13.5M Buy
+35,857
New +$13.9M 0.82% 62

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Impactive Capital
Impactive Capital New York City, New York $1.4B AUM 13.97% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

2Xideas's CRL Position: Q1 2025 in Review

2Xideas sold out of Charles River Laboratories (CRL) in Q1 2025, closing a stake of 36,758 shares — an estimated $6.79M sold.

2Xideas first reported a position in CRL in Q4 2021 and held it in 13 quarters. The position peaked at $13.5M in Q4 2021. 565 funds tracked by Wall St. Rank hold CRL as of Q1 2025.

  • 2Xideas reported no remaining Charles River Laboratories position as of Q1 2025 after selling out during the quarter.
  • 2Xideas sold 36,758 Charles River Laboratories shares in Q1 2025, an estimated $6.79M.
  • 2Xideas first reported a position in Charles River Laboratories in Q4 2021 and held it in 13 quarters.
  • 2Xideas's Charles River Laboratories position peaked at $13.5M in Q4 2021.
  • 565 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2025.

Based on 2Xideas's 13F filing for Q1 2025, filed 15 May 2025.